
Pramodini Medicare Initial Public Offering Day 1 Opens 12 August 2026: Healthcare Company Subscription Open on BSE SME
Pramodini Medicare initial public offering: Day 1 open. Sub 12-14 Aug 2026. BSE SME. Healthcare and pharma sector. Apply via ASBA or UPI before 14 August.
Updated: 12 Aug 2026 • 10:14 am
Posted by:

The Pramodini Medicare initial public offering is open for subscription on 12 August 2026, with bidding running from 12 August 2026 to 14 August 2026. Today is Day 1 of subscription for the Pramodini Medicare initial public offering, making it time-sensitive for investors who wish to participate. The Pramodini Medicare initial public offering gives retail and institutional investors an opportunity to subscribe to shares of Pramodini Medicare before the company lists on BSE SME. All applications for the Pramodini Medicare initial public offering must be submitted through the ASBA mechanism or UPI-linked demat accounts before the close of bidding on 14 August 2026.
Pramodini Medicare is a healthcare and pharmaceutical company providing medical products and healthcare services across domestic markets. The Pramodini Medicare initial public offering represents Pramodini Medicare's entry into the public capital markets. India's IPO market in August 2026 is active with multiple offerings open simultaneously, and the Pramodini Medicare initial public offering is one of the offerings investors tracking the primary market should evaluate carefully this week. The Healthcare and Pharmaceuticals sector background of the Pramodini Medicare initial public offering and the company's financial profile disclosed in the draft red herring prospectus are the key parameters for evaluating whether to apply for the Pramodini Medicare initial public offering.
Click Here – Get Free Investment Predictions
What Is the Pramodini Medicare initial public offering?
The Pramodini Medicare initial public offering is a public equity offering that invites investors to subscribe to shares of Pramodini Medicare at the price determined through the book-building or fixed price process as specified in the prospectus. The Pramodini Medicare initial public offering is listed on BSE SME and regulated by SEBI. Proceeds from the Pramodini Medicare initial public offering will be used by Pramodini Medicare as outlined in the DRHP filed with SEBI, typically for business expansion, working capital, and general corporate purposes.
Investors evaluating the Pramodini Medicare initial public offering should review the company's revenue growth, profitability track record, debt levels, promoter background, and competitive position in the Healthcare and Pharmaceuticals industry. The Pramodini Medicare initial public offering valuation at the issue price should be compared to listed peers in the Healthcare and Pharmaceuticals space to assess whether the offering is attractively priced. All relevant data for evaluating the Pramodini Medicare initial public offering is available in the DRHP filed on the SEBI EDGAR portal.
| Detail | Information |
|---|---|
| Company Name | Pramodini Medicare |
| Sector | Healthcare and Pharmaceuticals |
| Exchange | BSE SME |
| Subscription Opens | 12 August 2026 |
| Subscription Closes | 14 August 2026 |
| Subscription Day (12 Aug) | Day 1 |
| Application Method | ASBA / UPI |
| GMP Tracking | Not published by Univest — check tracker platforms |
Pramodini Medicare initial public offering: How to Apply
To apply for the Pramodini Medicare initial public offering, investors should log into their broker's trading platform or bank's net banking portal and navigate to the current IPO section. Select the Pramodini Medicare listing, enter the number of lots you wish to bid for, and confirm the bid price as specified in the Pramodini Medicare initial public offering prospectus. For UPI-based applications for the Pramodini Medicare initial public offering, enter your registered UPI ID and approve the mandate request within the time allowed by your UPI app. Ensure your demat account is KYC-compliant and linked to an ASBA-enabled bank account before submitting your application for the Pramodini Medicare initial public offering.
Retail investors applying for the Pramodini Medicare initial public offering should bid at the cutoff price to maximise their chances of allotment. The minimum lot size for the Pramodini Medicare initial public offering is specified in the prospectus and represents the smallest number of shares an investor can apply for. Applications for the Pramodini Medicare initial public offering below the minimum lot size will be rejected. The Pramodini Medicare initial public offering allotment will be done by lottery among all valid retail applicants if the retail portion is oversubscribed.
Explore Pramodini Medicare and the Full IPO Calendar on Univest Research Screener
Pramodini Medicare initial public offering: Grey Market Premium and Subscription Status
Investors tracking the Pramodini Medicare initial public offering subscription activity should note that Univest does not publish grey market premium figures for the Pramodini Medicare initial public offering or any other initial public offering. Grey market premium is an unofficial indicator that is not regulated or endorsed by SEBI, NSE, or BSE, and can vary widely between tracker platforms. For grey market premium data on the Pramodini Medicare initial public offering, investors should refer to dedicated GMP tracking platforms while understanding that such data does not guarantee listing performance.
The Pramodini Medicare initial public offering subscription status is available on the NSE and BSE websites, which publish live subscription data by investor category (QIB, NII, RII) throughout each day of bidding. High subscription in the QIB and NII categories is generally considered a positive signal for the Pramodini Medicare initial public offering, though it does not guarantee listing gains. Investors should evaluate the Pramodini Medicare initial public offering fundamentally and not rely solely on subscription figures or GMP data.
Download the Univest iOS App or Univest Android App to track the Pramodini Medicare initial public offering and IPO calendar from Univest.
Conclusion
The Pramodini Medicare initial public offering is open for subscription from 12 August 2026 to 14 August 2026, with Day 1 of bidding underway on 12 August 2026. The Pramodini Medicare initial public offering provides investors with an opportunity to participate in the public listing of Pramodini Medicare in the Healthcare and Pharmaceuticals sector. Investors should read the prospectus, evaluate the Pramodini Medicare initial public offering on business fundamentals and valuation, and consult a SEBI-registered financial advisor before applying. Allotment for the Pramodini Medicare initial public offering will be announced after the subscription window closes on 14 August 2026.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the Pramodini Medicare initial public offering?
Ans. The Pramodini Medicare initial public offering is an initial public offering by Pramodini Medicare, a Healthcare and Pharmaceuticals company. The Pramodini Medicare initial public offering is open for subscription from 12 August 2026 to 14 August 2026. Investors can apply for the Pramodini Medicare initial public offering through the ASBA mechanism or UPI-linked demat accounts. Check the official SEBI EDGAR portal for the complete prospectus and all details of the Pramodini Medicare initial public offering before subscribing.
What are the subscription dates for the This offering?
Ans. The The public issue subscription window is open from 12 August 2026 to 14 August 2026. Today is Day 1 of subscription for the The issue. Investors who wish to participate in the This public offering must submit their applications through ASBA or UPI before the close of bidding on 14 August 2026. Late applications will not be accepted for the The subscription.
What is the grey market premium for the This listing?
Ans. Univest does not publish grey market premium figures. Grey market premium is an unofficial and unregulated indicator collected informally outside the stock exchanges. It is not published, verified or endorsed by SEBI, NSE or BSE, can vary widely between trackers, and is not always accurate. For grey market premium data, refer to dedicated GMP tracker platforms and exercise caution when using such information for investment decisions related to any initial public offering.
How can I apply for the This offering?
Ans. Investors can apply for the The public issue through ASBA by logging into their bank's net banking or broker trading platform and selecting the Pramodini Medicare IPO. For UPI-based applications for the The issue, enter your UPI ID during the application and approve the mandate request within the stipulated time. Apply at the cutoff price to maximise allotment chances in the This public offering.
What categories of investors can apply for the The subscription?
Ans. The This listing is open to Retail Individual Investors (RII), Non-Institutional Investors (NII/HNI), and Qualified Institutional Buyers (QIB) in their respective reservation categories. Retail investors can apply for the This offering up to a maximum of Rs 2 lakh per application. Check the The public issue prospectus for exact lot size and per-category application limits.
What are the key risks of investing in the The issue?
Ans. Key risks of the This public offering include limited post-listing liquidity typical of smaller public offerings, sector-specific challenges in the Healthcare and Pharmaceuticals space, valuation uncertainty at the issue price relative to listed peers, and general market risk. The The subscription is not a guaranteed profit opportunity. Read the DRHP risk factors carefully and consult a SEBI-registered advisor before investing.
When is the allotment date for the This listing?
Ans. The allotment date for the This offering will be announced after the subscription window closes on 14 August 2026. Allotment for the The public issue is typically completed within 6 working days of the close of subscription. Investors can check their The issue allotment status on the BSE or NSE website using their application number or PAN after the announced allotment date.
Recent Articles

PI Industries Q1 FY27 Results: Revenue Rs 1,702 Cr, PAT Rs 242 Cr and Key Highlights
12 August 2026

Electronics Mart India Q1 FY27 Results: Revenue Rs 2,418 Cr, PAT Rs 120 Cr and Key Highlights
12 August 2026

Rail Vikas Nigam Q1 FY27 Results: Revenue Rs 4,321 Cr, PAT Rs 153 Cr and Key Highlights
12 August 2026

Entero Healthcare Q1 FY27 Results: Revenue Rs 1,940 Cr, PAT Rs 52 Cr and Key Highlights
12 August 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
PI Industries Q1 FY27 Results: Revenue Rs 1,702 Cr, PAT Rs 242 Cr and Key Highlights
Electronics Mart India Q1 FY27 Results: Revenue Rs 2,418 Cr, PAT Rs 120 Cr and Key Highlights
Rail Vikas Nigam Q1 FY27 Results: Revenue Rs 4,321 Cr, PAT Rs 153 Cr and Key Highlights
Entero Healthcare Q1 FY27 Results: Revenue Rs 1,940 Cr, PAT Rs 52 Cr and Key Highlights
MRF Q1 FY27 Results: Revenue Rs 8,415 Cr, PAT Rs 495 Cr and Key Highlights

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





